Adnan Khattak
Edith Cowan University · 93 works · 7,150 citations · h-index 24
Top works
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study
- Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
- Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
- Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
- Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial
- Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study
- Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
- Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
- Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial
- Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
- Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial
- Utilisation of geriatric assessment in oncology - a survey of Australian medical oncologists